Generic Name and Formulations:
Potassium citrate 5mEq (540mg), 10mEq (1080mg), 15mEq (1620mg); tabs.
Mission Pharmacal Company
- Migraine Associated With Increased Risk for Postsurgical 30-Day Hospital Readmission for Pain
- Population-Based Incidence of Acute Idiopathic Optic Neuritis Estimated
- High Treatment Adherence and Quality of Life Observed With Fingolimod
Indications for UROCIT-K:
Renal tubular acidosis with calcium stones. Hypocitraturic calcium oxalate nephrolithiasis. Uric acid lithiasis.
Take within 30 minutes of meals or bedtime snack. Adjust based on urinary citrate levels and/or pH. Urinary citrate <150mg/day: 30mEq twice daily or 20mEq 3 times daily. Urinary citrate >150mEq/day: 15mEq twice daily or 10mEq 3 times daily. Max 100mEq/day.
See literature. Hyperkalemia or predisposing conditions. GI narrowing or stricture, delayed gastric emptying or predisposing conditions. Peptic ulcer disease. UTI. Renal insufficiency (GFR <0.7mL/kg per minute).
Restrict salt intake and encourage high fluid intake. Discontinue if severe vomiting, GI pain or bleeding occurs and follow-up. Monitor 24 hour urinary citrate, urinary pH, serum electrolytes, CBC, ECG, at least every 4 months; discontinue if hyperkalemia, significant rise in serum creatinine, or significant fall in hematocrit or hemoglobin occurs. Pregnancy (Cat.C). Nursing mothers.
Contraindicated with potassium-sparing diuretics, anticholinergics, other drugs that slow GI motility. Monitor digoxin. May interfere with some urinary tract antibiotics. Caution with drugs that raise serum potassium.
Hyperkalemia, GI upset, irritation, bleeding.
Neurology Advisor Articles
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications